Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


New Coronavirus Variant May Have Implications For Vaccine Composition

UK Pharma Industry Assessing Impact Of Transport Restrictions

Executive Summary

Close monitoring of the effectiveness of coronavirus vaccines will be necessary after a new variant of SARS-CoV-2 was reported to be causing a rapid increase in transmission of the virus in the UK. The pharmaceutical industry says companies are not expecting travel restrictions imposed on the UK to have an impact on the supply of medicines.

You may also be interested in...

EMA To Advise On Tweaking COVID-19 Vaccines Due To New Variants

Concerns that new or future mutations of the novel coronavirus may reduce the protection offered by existing COVID-19 vaccines have prompted the European Medicines Agency to develop guidance to help vaccine manufacturers who are planning to alter to their products.

Pfizer/BioNTech COVID-19 Vaccine Wins EU Approval

The first COVID-19 vaccine will shortly be available to the EU member states, after the European Commission today approved Pfizer/BioNTech's BNT162b2 just hours after the European Medicines Agency issued a positive opinion on the product. The EMA says that uncertainties remain over the ability of the vaccine to prevent transmission of the coronavirus and whether the new variant strain will render this and other vaccines less effective. 

Coronavirus Notebook: UK Begins COVID-19 Vaccine Rollout, Government May Enlist Military Backup

EU passes legislation allowing VAT exemption for coronavirus vaccines to make them more affordable, as two treatments for severe disease and “Long COVID” respectively enter Phase II trials.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts